Literature DB >> 3801854

Parkinson's disease. Cognitive changes in relation to treatment response.

A E Taylor, J A Saint-Cyr, A E Lang.   

Abstract

Four groups of patients with Parkinson's disease matched for age, education and IQ were categorized by response to treatment and compared with a normal control group. The patient groups were (1) No Treatment (de novo); (2) Good Response (including minor fluctuations in symptoms); (3) Fluctuations (significant, including 'on-off' phenomena) and/or marked Abnormal Involuntary Movements (dyskinesias); and (4) Poor Response ('secondary treatment failure' characterized by significant deterioration over time in all major symptoms). As a previous investigation had established that neuropsychological tests thought to be sensitive to the functional integrity of the frontal lobes are selectively impaired in Parkinson's disease, the first phase of this study compared the five groups on five such tests and two tests of psychomotor ability. While all patient groups displayed deficits on the psychomotor tests and on several tests associated with frontal lobe function compared with normals, only the Poor Response group was impaired on all tasks. In a second phase, comprehensive testing of additional cognitive processes such as attention, mnemonic, and visuospatial functions, the latter two traditionally thought to depend primarily on posterior cortical regions, revealed no significant cognitive deficits in any patient group. Results are discussed with respect to the involvement of the nigrostriatal and mesocortical dopaminergic systems.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3801854     DOI: 10.1093/brain/110.1.35

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  8 in total

1.  Differential memory and executive functions in demented patients with Parkinson's and Alzheimer's disease.

Authors:  I Litvan; E Mohr; J Williams; C Gomez; T N Chase
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-01       Impact factor: 10.154

2.  Cognitive functioning after pallidotomy for refractory Parkinson's disease.

Authors:  K Perrine; M Dogali; E Fazzini; D Sterio; E Kolodny; D Eidelberg; O Devinsky; A Beric
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-08       Impact factor: 10.154

Review 3.  Neuropsychological aspects of Parkinson's disease.

Authors:  S A Raskin; J C Borod; J Tweedy
Journal:  Neuropsychol Rev       Date:  1990-09       Impact factor: 7.444

Review 4.  The ageing brain: normal and abnormal memory.

Authors:  M S Albert
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1997-11-29       Impact factor: 6.237

5.  Impairment in dating and retrieving remote events in patients with early Parkinson's disease.

Authors:  A Venneri; P Nichelli; G Modonesi; M A Molinari; R Russo; C Sardini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-04       Impact factor: 10.154

Review 6.  Role of dopamine in learning and memory: implications for the treatment of cognitive dysfunction in patients with Parkinson's disease.

Authors:  J Kulisevsky
Journal:  Drugs Aging       Date:  2000-05       Impact factor: 3.923

7.  Mild cognitive impairment in Parkinson's disease: the challenge and the promise.

Authors:  Hubert H Fernandez; Gregory P Crucian; Michael S Okun; Catherine C Price; Dawn Bowers
Journal:  Neuropsychiatr Dis Treat       Date:  2005-03       Impact factor: 2.570

Review 8.  The Pharmacological Potential of Adenosine A2A Receptor Antagonists for Treating Parkinson's Disease.

Authors:  Akihisa Mori; Jiang-Fan Chen; Shinichi Uchida; Cecile Durlach; Shelby M King; Peter Jenner
Journal:  Molecules       Date:  2022-04-06       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.